{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:26:33Z","timestamp":1785277593964,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1103165"],"award-info":[{"award-number":["1103165"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp & Dohme, Australia"},{"DOI":"10.13039\/100017037","name":"Cepheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015069","name":"South Eastern Sydney Local Health District","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>There is limited research on health-related quality of life (HRQoL) among people who inject drugs (PWID). We aimed to evaluate factors associated with HRQoL among a cohort of PWID in Australia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants were enrolled in an observational cohort study (the LiveRLife Study) between 2014 and 2018 at 15 sites in Australia. They provided fingerstick whole-blood samples for point-of-care HCV RNA testing and underwent transient elastography to assess liver disease. Participants completed the EQ-5D-3L survey at enrolment. Regression models were used to assess the impact of clinical and socioeconomic characteristics on the EQ-5D-3L scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 751 participants (median age, 43\u00a0years; 67% male), 63% reported injection drug use in the past month, 43% had current HCV infection, and 68% had no\/mild liver fibrosis (F0\/F1). The mean EQ-5D-3L and EQ-VAS scores were 0.67 and 62, respectively, for the overall study population. There was no significant difference in the EQ-5D-3L scores among people with and without recent injecting drug use (mean: 0.66 vs. 0.68, median: 0.73 vs. 0.78, P\u2009=\u20090.405), and among people receiving and not receiving opioid agonist therapy (mean: 0.66 vs. 0.68, median: 0.73 vs. 0.76, P\u2009=\u20090.215). Participants who were employed were found to have the highest mean EQ-5D-3L (0.83) and EQ-VAS scores (77). The presence of current HCV infection, liver fibrosis stage, and high-risk alcohol consumption had little impact on HRQoL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study findings provide important HRQoL data for economic evaluations, useful for guiding the allocation of resources for HCV elimination strategies and interventions among PWID.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11136-023-03465-3","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T18:42:29Z","timestamp":1687545749000},"page":"3195-3207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health-related quality of life among people who inject drugs in Australia"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-8760","authenticated-orcid":false,"given":"Qinglu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Bajis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophy T. F.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison D.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Hajarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"issue":"7","key":"3465_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40273-016-0389-9","volume":"34","author":"M Karimi","year":"2016","unstructured":"Karimi, M., & Brazier, J. (2016). Health, health-related quality of life, and quality of life: What is the difference? PharmacoEconomics, 34(7), 645\u2013649.","journal-title":"PharmacoEconomics"},{"issue":"5","key":"3465_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178474","volume":"12","author":"N Scott","year":"2017","unstructured":"Scott, N., Carrotte, E. R., Higgs, P., Stoov\u00e9, M. A., Aitken, C. K., & Dietze, P. M. (2017). Longitudinal changes in personal wellbeing in a cohort of people who inject drugs. PLoS ONE, 12(5), e0178474.","journal-title":"PLoS ONE"},{"issue":"3","key":"3465_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/jphd.12092","volume":"75","author":"A Truong","year":"2015","unstructured":"Truong, A., Higgs, P., Cogger, S., Jamieson, L., Burns, L., & Dietze, P. (2015). Oral health-related quality of life among an Australian sample of people who inject drugs. Journal of Public Health Dentistry, 75(3), 218\u2013224.","journal-title":"Journal of Public Health Dentistry"},{"issue":"1","key":"3465_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/add.14393","volume":"114","author":"J Grebely","year":"2019","unstructured":"Grebely, J., Larney, S., Peacock, A., Colledge, S., Leung, J., Hickman, M., Vickerman, P., Blach, S., Cunningham, E. B., Dumchev, K., Lynskey, M., Stone, J., Trickey, A., Razavi, H., Mattick, R. P., Farrell, M., Dore, G. J., & Degenhardt, L. (2019). Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 114(1), 150\u2013166.","journal-title":"Addiction"},{"issue":"1","key":"3465_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/hep.20014","volume":"39","author":"O Dalgard","year":"2004","unstructured":"Dalgard, O., Egeland, A., Skaug, K., Vilimas, K., & Steen, T. (2004). Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology, 39(1), 74\u201380.","journal-title":"Hepatology"},{"issue":"3","key":"3465_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2012.11.004","volume":"58","author":"SA McDonald","year":"2013","unstructured":"McDonald, S. A., Hutchinson, S. J., Palmateer, N. E., Allen, E., Cameron, S. O., Goldberg, D. J., & Taylor, A. (2013). Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. Journal of Hepatology, 58(3), 460\u2013466.","journal-title":"Journal of Hepatology"},{"issue":"10","key":"3465_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163488","volume":"11","author":"DK van Santen","year":"2016","unstructured":"van Santen, D. K., de Vos, A. S., Matser, A., Willemse, S. B., Lindenburg, K., Kretzschmar, M. E. E., Prins, M., & de Wit, G. A. (2016). Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; Extrapolating from Amsterdam, the Netherlands. PLoS ONE, 11(10), e0163488.","journal-title":"PLoS ONE"},{"issue":"4","key":"3465_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/jgh.12041","volume":"28","author":"AJ Visconti","year":"2013","unstructured":"Visconti, A. J., Doyle, J. S., Weir, A., Shiell, A. M., & Hellard, M. E. (2013). Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. Journal of Gastroenterology and Hepatology, 28(4), 707\u2013716.","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"8","key":"3465_CR9","volume":"3","author":"NK Martin","year":"2013","unstructured":"Martin, N. K., Hickman, M., Miners, A., Hutchinson, S. J., Taylor, A., & Vickerman, P. (2013). Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. British Medical Journal Open, 3(8), e003153.","journal-title":"British Medical Journal Open"},{"issue":"12","key":"3465_CR10","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1111\/add.14731","volume":"114","author":"C Barbosa","year":"2019","unstructured":"Barbosa, C., Fraser, H., Hoerger, T. J., Leib, A., Havens, J. R., Young, A., Kral, A., Page, K., Evans, J., Zibbell, J., Hariri, S., Vellozzi, C., Nerlander, L., Ward, J. W., & Vickerman, P. (2019). Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction, 114(12), 2267\u20132278.","journal-title":"Addiction"},{"issue":"9","key":"3465_CR11","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/cid\/ciab669","volume":"74","author":"MA Gormley","year":"2022","unstructured":"Gormley, M. A., Akiyama, M. J., Rennert, L., Howard, K. A., Norton, B. L., Pericot-Valverde, I., Muench, S., Heo, M., & Litwin, A. H. (2022). Changes in health-related quality of life for hepatitis C virus-infected people who inject drugs while on opioid agonist treatment following sustained virologic response. Clinical Infectious Diseases, 74(9), 1586\u20131593.","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"3465_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/jvh.13112","volume":"26","author":"S Bajis","year":"2019","unstructured":"Bajis, S., Grebely, J., Cooper, L., Smith, J., Owen, G., Chudleigh, A., Hajarizadeh, B., Martinello, M., Adey, S., Read, P., Gilliver, R., Applegate, T., Treloar, C., Maher, L., & Dore, G. J. (2019). Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. Journal of Viral Hepatitis, 26(8), 969\u2013979.","journal-title":"Journal of Viral Hepatitis"},{"issue":"3","key":"3465_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jvh.13233","volume":"27","author":"S Bajis","year":"2020","unstructured":"Bajis, S., Grebely, J., Hajarizadeh, B., Applegate, T., Marshall, A. D., Ellen Harrod, M., Byrne, J., Bath, N., Read, P., Edwards, M., Gorton, C., Hayllar, J., Cock, V., Peterson, S., Thomson, C., Weltman, M., Jefferies, M., Wood, W., Haber, P., et al. (2020). Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 27(3), 281\u2013293.","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"3465_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P., & De L\u00e9dinghen, V. (2005). Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 128(2), 343\u2013350.","journal-title":"Gastroenterology"},{"issue":"16","key":"3465_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","volume":"158","author":"K Bush","year":"1998","unstructured":"Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D., & Bradley, K. A. (1998). The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Archives of Internal Medicine, 158(16), 1789\u20131795.","journal-title":"Archives of Internal Medicine"},{"issue":"7","key":"3465_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/j.1530-0277.2007.00403.x","volume":"31","author":"KA Bradley","year":"2007","unstructured":"Bradley, K. A., DeBenedetti, A. F., Volk, R. J., Williams, E. C., Frank, D., & Kivlahan, D. R. (2007). AUDIT-C as a brief screen for alcohol misuse in primary care. Alcoholism, Clinical and Experimental Research, 31(7), 1208\u20131217.","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"7","key":"3465_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/archinte.163.7.821","volume":"163","author":"KA Bradley","year":"2003","unstructured":"Bradley, K. A., Bush, K. R., Epler, A. J., Dobie, D. J., Davis, T. M., Sporleder, J. L., Maynard, C., Burman, M. L., & Kivlahan, D. R. (2003). Two brief alcohol-screening tests from the alcohol use disorders identification test (AUDIT): Validation in a female veterans affairs patient population. Archives of Internal Medicine, 163(7), 821\u2013829.","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"3465_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jval.2011.04.009","volume":"14","author":"R Viney","year":"2011","unstructured":"Viney, R., Norman, R., King, M. T., Cronin, P., Street, D. J., Knox, S., & Ratcliffe, J. (2011). Time trade-off derived EQ-5D weights for Australia. Value Health, 14(6), 928\u2013936.","journal-title":"Value Health"},{"issue":"1","key":"3465_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1536867X1501500102","volume":"15","author":"F Belotti","year":"2015","unstructured":"Belotti, F., Deb, P., Manning, W. G., & Norton, E. C. (2015). twopm: Two-part models. Stata Journal, 15(1), 3\u201320.","journal-title":"Stata Journal"},{"issue":"8","key":"3465_CR20","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s11136-014-0676-x","volume":"23","author":"S Clemens","year":"2014","unstructured":"Clemens, S., Begum, N., Harper, C., Whitty, J. A., & Scuffham, P. A. (2014). A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Quality of Life Research, 23(8), 2375\u20132381.","journal-title":"Quality of Life Research"},{"issue":"8","key":"3465_CR21","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s11136-013-0350-8","volume":"22","author":"JA Fischer","year":"2013","unstructured":"Fischer, J. A., Conrad, S., Clavarino, A. M., Kemp, R., & Najman, J. M. (2013). Quality of life of people who inject drugs: Characteristics and comparisons with other population samples. Quality of Life Research, 22(8), 2113\u20132121.","journal-title":"Quality of Life Research"},{"issue":"5","key":"3465_CR22","doi-asserted-by":"publisher","first-page":"e0215596","DOI":"10.1371\/journal.pone.0215596","volume":"14","author":"S Cossais","year":"2019","unstructured":"Cossais, S., Schwarzinger, M., Pol, S., Fontaine, H., Larrey, D., Pageaux, G.-P., Canva, V., Mathurin, P., Yazdanpanah, Y., & Deuffic-Burban, S. (2019). Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage. PLoS ONE, 14(5), e0215596\u2013e0215596.","journal-title":"PLoS ONE"},{"issue":"1","key":"3465_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40258-020-00600-w","volume":"19","author":"R Han","year":"2021","unstructured":"Han, R., Fran\u00e7ois, C., & Toumi, M. (2021). Systematic review of health state utility values used in European pharmacoeconomic evaluations for chronic hepatitis C: Impact on cost-effectiveness results. Applied Health Economics and Health Policy, 19(1), 29\u201344.","journal-title":"Applied Health Economics and Health Policy"},{"issue":"2","key":"3465_CR24","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S2468-2667(21)00258-9","volume":"7","author":"J Stone","year":"2022","unstructured":"Stone, J., Artenie, A., Hickman, M., Martin, N. K., Degenhardt, L., Fraser, H., & Vickerman, P. (2022). The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: A modelling study. The Lancet Public Health, 7(2), e136\u2013e145.","journal-title":"The Lancet Public Health"},{"key":"3465_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jval.2022.12.016","volume":"26","author":"Q Cheng","year":"2023","unstructured":"Cheng, Q., Cunningham, E. B., Shih, S., Amin, J., Bruneau, J., Artenie, A. A., Powis, J., Litwin, A. H., Cooper, C., Dalgard, O., Hellard, M., Bruggmann, P., Marks, P., Lacombe, K., Stedman, C., Read, P., Hajarizadeh, B., Dunlop, A. J., Conway, B., et al. (2023). Patient-reported outcomes during and after hepatitis c virus direct-acting antiviral treatment among people who inject drugs. Value Health, 26, 883\u2013892.","journal-title":"Value Health"},{"key":"3465_CR26","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/add.16169","volume":"118","author":"SA McDonald","year":"2023","unstructured":"McDonald, S. A., Myring, G., Palmateer, N. E., McAuley, A., Beer, L., Dillon, J. F., Hollingworth, W., Gunson, R., Hickman, M., & Hutchinson, S. J. (2023). Improved health-related quality of life after hepatitis C viraemic clearance among people who inject drugs may not be durable. Addiction, 118, 1340\u20131350.","journal-title":"Addiction"},{"issue":"1","key":"3465_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13011-020-00309-y","volume":"15","author":"CF Aas","year":"2020","unstructured":"Aas, C. F., Vold, J. H., Skurtveit, S., Lim, A. G., Ruths, S., Islam, K., Askildsen, J. E., L\u00f8berg, E.-M., Fadnes, L. T., Johansson, K. A., Aas, C. F., Buljovcic, V. B., Chalabianloo, F., Daltveit, J. T., Alpers, S. E., Fadnes, L. T., Eriksen, T. F., Gundersen, P., Hille, V., et al. (2020). Health-related quality of life of long-term patients receiving opioid agonist therapy: A nested prospective cohort study in Norway. Substance Abuse Treatment, Prevention, and Policy, 15(1), 68.","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"3465_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.drugalcdep.2013.10.011","volume":"134","author":"JP Feelemyer","year":"2014","unstructured":"Feelemyer, J. P., Jarlais, D. C. D., Arasteh, K., Phillips, B. W., & Hagan, H. (2014). Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review. Drug and Alcohol Dependence, 134, 251\u2013258.","journal-title":"Drug and Alcohol Dependence"},{"key":"3465_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2015.10.009","volume":"157","author":"B Nosyk","year":"2015","unstructured":"Nosyk, B., Bray, J. W., Wittenberg, E., Aden, B., Eggman, A. A., Weiss, R. D., Potter, J., Ang, A., Hser, Y. I., Ling, W., & Schackman, B. R. (2015). Short term health-related quality of life improvement during opioid agonist treatment. Drug and Alcohol Dependence, 157, 121\u2013128.","journal-title":"Drug and Alcohol Dependence"},{"issue":"2\u20133","key":"3465_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.drugalcdep.2011.04.003","volume":"118","author":"B Nosyk","year":"2011","unstructured":"Nosyk, B., Guh, D. P., Sun, H., Oviedo-Joekes, E., Brissette, S., Marsh, D. C., Schechter, M. T., & Anis, A. H. (2011). Health related quality of life trajectories of patients in opioid substitution treatment. Drug and Alcohol Dependence, 118(2\u20133), 259\u2013264.","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"3465_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/00952990.2011.649222","volume":"38","author":"PW Wang","year":"2012","unstructured":"Wang, P. W., Wu, H. C., Yen, C. N., Yeh, Y. C., Chung, K. S., Chang, H. C., & Yen, C. F. (2012). Change in quality of life and its predictors in heroin users receiving methadone maintenance treatment in Taiwan: An 18-month follow-up study. American Journal of Drug and Alcohol Abuse, 38(3), 213\u2013219.","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"3465_CR32","doi-asserted-by":"crossref","unstructured":"EuroQol--a new facility for the measurement of health-related quality of life. Health Policy, 1990. 16(3): p. 199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"1","key":"3465_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ibd.20989","volume":"16","author":"RG Stark","year":"2010","unstructured":"Stark, R. G., Reitmeir, P., Leidl, R., & K\u00f6nig, H.-H. (2010). Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflammatory Bowel Diseases, 16(1), 42\u201351.","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"3465_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12955-021-01731-x","volume":"19","author":"H Short","year":"2021","unstructured":"Short, H., Al Sayah, F., Ohinmaa, A., & Johnson, J. A. (2021). The performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings. Health and Quality of Life Outcomes, 19(1), 96.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"1","key":"3465_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-8-13","volume":"8","author":"MTD Dyer","year":"2010","unstructured":"Dyer, M. T. D., Goldsmith, K. A., Sharples, L. S., & Buxton, M. J. (2010). A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health and Quality of Life Outcomes, 8(1), 13.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"7","key":"3465_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/09540121.2016.1173639","volume":"28","author":"N Mafirakureva","year":"2016","unstructured":"Mafirakureva, N., Dzingirai, B., Postma, M. J., van Hulst, M., & Khoza, S. (2016). Health-related quality of life in HIV\/AIDS patients on antiretroviral therapy at a tertiary care facility in Zimbabwe. AIDS Care, 28(7), 904\u2013912.","journal-title":"AIDS Care"},{"issue":"2","key":"3465_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11136-013-0505-7","volume":"23","author":"RT Anderson","year":"2014","unstructured":"Anderson, R. T., Baran, R. W., Dietz, B., Kallwitz, E., Erickson, P., & Revicki, D. A. (2014). Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument. Quality of Life Research, 23(2), 561\u2013570.","journal-title":"Quality of Life Research"},{"key":"3465_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103906","volume":"111","author":"M Spaderna","year":"2022","unstructured":"Spaderna, M., Kattakuzhy, S., Kang, S. J., George, N., Bijole, P., Ebah, E., Eyasu, R., Ogbumbadiugha, O., Silk, R., Gannon, C., Davis, A., Cover, A., Gayle, B., Narayanan, S., Pao, M., Kottilil, S., & Rosenthal, E. (2022). Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use. The International Journal on Drug Policy, 111, 103906.","journal-title":"The International Journal on Drug Policy"},{"issue":"1","key":"3465_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11136-022-03209-9","volume":"32","author":"M K\u00e5berg","year":"2023","unstructured":"K\u00e5berg, M., Larsson, S., Bergstr\u00f6m, J., & Hammarberg, A. (2023). Quality-adjusted life years among people who inject drugs in a needle syringe program in Sweden. Quality of Life Research, 32(1), 197\u2013207.","journal-title":"Quality of Life Research"},{"issue":"1","key":"3465_CR40","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1186\/s12889-021-12009-8","volume":"21","author":"J Stephenson","year":"2021","unstructured":"Stephenson, J., Smith, C. M., Kearns, B., Haywood, A., & Bissell, P. (2021). The association between obesity and quality of life: A retrospective analysis of a large-scale population-based cohort study. BMC Public Health, 21(1), 1990.","journal-title":"BMC Public Health"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-023-03465-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-023-03465-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-023-03465-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T18:15:41Z","timestamp":1695752141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-023-03465-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["3465"],"URL":"https:\/\/doi.org\/10.1007\/s11136-023-03465-3","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"12 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GD has received research grants from AbbVie, Gilead Sciences and Merck. JG is a consultant\/advisor and has received research grants from AbbVie, Camurus, Cepheid, Gilead Sciences, Hologic, Indivior and Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol and amendments were approved by the Human Research Ethics Committee at St. Vincent's Hospital, Sydney (HREC\/12\/SVH\/34).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}